Revenue - Revenue Collaboration Partnership Concentration (Details) - Revenue	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Customer | BioRidge Pharma, LLC
Disaggregation of Revenue [Line Items]
Concentration risk (percent)	65.90%	75.40%	24.00%
Customer | Cardinal Health
Disaggregation of Revenue [Line Items]
Concentration risk (percent)	21.40%	14.50%	19.80%
Customer | McKesson Corporation
Disaggregation of Revenue [Line Items]
Concentration risk (percent)	17.90%	14.10%	15.70%
Customer | Cencora (formerly AmerisourceBergen Drug Corporation)
Disaggregation of Revenue [Line Items]
Concentration risk (percent)	17.30%	16.40%	19.10%
Collaboration partners | Kyowa Kirin
Disaggregation of Revenue [Line Items]
Concentration risk (percent)	5.90%	4.30%	29.00%